Treatment Landscape in HR+, HER2- MBC

 

Treatment Landscape in HR+, HER2- MBC
30:46

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"

FEATURING Sara Tolaney, Hope Rugo
  • 1,057 views
  • November 3, 2023
  • 10
17:20

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-756 & BEGONIA"

FEATURING Paolo Tarantino
  • 1,716 views
  • November 3, 2023
  • 12
08:40

PrecisCa

Managing Common Toxicities From CDK4/6i

FEATURING Erin Shonkwiler
  • 136 views
  • August 18, 2023
  • 1
08:51

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Effects of Ovarian Ablation or Suppression on BC Recurrence and Survival - Patient-Level Meta-Analysis of 14,993 Pre-Menopausal Women in 25 Randomized Trials"

FEATURING Richard Gray
  • 324 views
  • June 16, 2023
  • 3
05:27

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Final Results of the Phase 3 SAFE Trial - Pharmacological Cardioprotective Strategy for Non-Metastatic Patients Affected by BC Receiving an Anthracycline-Based Chemo"

FEATURING Carlotta Becherini, Lorenzo Livi
  • 199 views
  • June 12, 2023
  • 2
06:55

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Comparative OS of Pts in Trials of CKD4/6i in Combination With ET in Advanced BC"

FEATURING Coralea Kappel
  • 315 views
  • June 9, 2023
  • 1
13:35

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Subgroup Analysis of the RIGHT Choice Trial - Outcomes With 1L Ribociclib + ET vs. Physician’s Choice Combination Chemo by Age in Pre/Perimenopausal Pts With Aggressive HR+/HER2- aBC"

FEATURING Nagi El Saghir
  • 234 views
  • June 9, 2023
  • 2
19:21

Abirami Sivapiragasam

Sequencing Treatment Options for HR+ mBC

  • 205 views
  • May 11, 2023
  • 3
12:44

SABCS 2022 Conference Coverage

SABCS 2022 Primary Results From the Randomized Phase II RIGHT Choice Trial: Premenopausal Patients With Aggressive HR+/HER2- Advanced BC Treated With Ribociclib + ET vs. Physician’s Choice Combination Chemo

FEATURING Yen-Shen Lu
  • 170 views
  • January 20, 2023
19:12

Penn Medicine Abramson Cancer Center

Updates in HR+ mBC

FEATURING Igor Makhlin
  • 241 views
  • January 12, 2023
  • 6
17:31

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Case Studies Discussion of Patients with HR+/HER2- mBC

FEATURING Natasha Hunter
  • 122 views
  • March 3, 2023
26:03

Total Health

HR+ mBC: Optimizing Endocrine Therapy

FEATURING Joyce O'Shaughnessy
  • 880 views
  • March 30, 2023
  • 4
20:16

University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L Setting

FEATURING Virginia Borges
  • 1,493 views
  • April 13, 2023
  • 9
19:02

Denise Yardley

Phase III Pooled MONALEESA Safety & Efficacy Data in HR+/HER2- mBC: Clinical Implications

  • 426 views
  • June 28, 2023
  • 2
10:43

Ahmad Awada

Recent Development in the Treatment of HR+/HER2- mBC

  • 198 views
  • August 3, 2023
  • 2
22:17

RWJBarnabas Health Rutgers Cancer Institute of New Jersey

Administration, Safety, and Dosing of Ribociclib for ER+/HER2- mBC

FEATURING Jackie Lauria
  • 186 views
  • September 26, 2023
  • 3
08:31

Neelam Desai

Comparing the Efficacy Data of CDK4/6i in HR+/HER2- mBC

  • 158 views
  • September 28, 2023
  • 2
13:35

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "The RIGHT Choice Trial - 1L Ribociclib + ET vs. Combination Chemo in Aggressive HR+/HER2- Advanced Breast Cancer"

FEATURING Hamdy Azim
  • 330 views
  • November 14, 2023
  • 7
12:08

West Cancer Center

Patient Selection for CDK4/6i in HR+/HER2- Advanced BC

FEATURING Gregory Vidal
  • 238 views
  • November 27, 2023
  • 1